Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

G8 Agrees World Will Tackle Alzheimer’s, But Solutions Are Some Way Off

This article was originally published in The Pink Sheet Daily

Executive Summary

The G8 dementia summit saw politicians, health stakeholders and financiers agree to target Alzheimer’s disease together, but a silver bullet may be years away.

You may also be interested in...



Dementia-Focused VC Fund Hopes To Succeed Where Other Research Strategies Have Not

A group of pharmaceutical companies, charities and the UK government are funding the first venture capital fund targeted against a specific condition, dementia.

Australia’s Prana Biotech Phase II Data On Huntington’s Candidate Holds Investor Interest With More To Come

Australia’s Prana Biotechnology has Phase II clinical trial data on a potential Huntington’s disease therapy to sustain a surge in the share price over the past year with more possibly on the way for an Alzheimer’s therapy.

Efficacy Signal For Lilly’s Solanezumab Stirs The Alzheimer’s Pot

With the potential for a multi-billion-dollar blockbuster on its hands, Eli Lilly could conduct a confirmatory trial or even seek near-term approval of sola after pooled data revealed a hint of disease modifying potential in mildly affected Alzheimer’s patients, though the company also may be grasping at straws.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS075146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel